Subscribe free

HPB & Spleen ·

Neoadjuvant Chemotherapy Did Not Beat Upfront Surgery for Resectable Pancreatic Head Cancer

Neoadjuvant chemotherapy did not improve survival over upfront pancreatoduodenectomy in resectable pancreatic head cancer, in a single-center retrospective cohort.

  • Overall survival and recurrence-free survival were similar across upfront surgery, neoadjuvant gemcitabine plus nab-paclitaxel, and neoadjuvant gemcitabine plus S-1.
  • A preoperative CA19-9 of 37 U/ml or higher was independently linked to worse overall survival.
  • Retrospective single-center cohort of 196 patients who underwent pancreaticoduodenectomy from 2012 to 2022, with groups of 112, 45, and 39.

Surgeons should not switch to neoadjuvant therapy on the basis of trial survival data alone, since this cohort did not reproduce that benefit. Preoperative CA19-9 may help identify patients with poorer prognosis who need closer selection for neoadjuvant treatment.

Journal Article by Kimura K, Sato S (…) Hirano S et 9 al. in J Gastrointest Oncol

© AME Publishing Company.

read the whole article in J Gastrointest Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in HPB & Spleen

The latest stitches

All papers in HPB & Spleen →